Stockscreener 앱 받기
23.71
3.42%
0.6058
Janux Therapeutics Inc 주식(JANX)의 최신 뉴스
Janux Therapeutics Becomes Oversold (JANX) - Nasdaq
Closing Figures Unveiled: Janux Therapeutics Inc (JANX) Drop -5.18, Closes at 23.61 - DWinneX
Janux Therapeutics, Inc. (JANX) Stock Analysis: Biotechnology Pioneer with 256.30% Potential Upside - DirectorsTalk Interviews
Where are the Opportunities in (JANX) - news.stocktradersdaily.com
Janux Therapeutics reports annual meeting results By Investing.com - Investing.com South Africa
Janux Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks
Janux Therapeutics reports annual meeting results - Investing.com
Advanced Renal Cell Carcinoma Pipeline 2025: In-depth Clinical - openPR.com
Equities Analysts Issue Forecasts for JANX FY2026 Earnings - Defense World
California State Teachers Retirement System Grows Stock Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
Janux Therapeutics (NASDAQ:JANX) Shares Up 7.9% – Time to Buy? - Defense World
Janux Therapeutics, Inc. (NASDAQ:JANX) Short Interest Update - Defense World
Janux Therapeutics: Advancing Tumor-Targeted Immunotherapy with Innovative T Cell Platform - majiroxnews.com
Janux Therapeutics, Inc. (NASDAQ:JANX) Position Lifted by Ameriprise Financial Inc. - Defense World
SA Asks: Which oncology companies are attractive M&A targets? - Seeking Alpha
Nuveen Asset Management LLC Sells 39,145 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
Millennium Management LLC Invests $6.22 Million in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
BNP Paribas Financial Markets Purchases New Position in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
When the Price of (JANX) Talks, People Listen - news.stocktradersdaily.com
Janux Therapeutics, Inc. (NASDAQ:JANX) Given Average Rating of “Buy” by Analysts - Defense World
How Vir Bio CEO Marianne De Backer Is Rebuilding Commercial Momentum - insights.citeline.com
How Vir CEO Marianne De Backer Is Rebuilding Commercial Momentum - insights.citeline.com
Janux appoints Janeen Doyle chief corporate, business development officer - TipRanks
Janux Therapeutics (JANX) Welcomes New Chief Corporate and Busin - GuruFocus
Janux Therapeutics (JANX) Welcomes New Chief Corporate and Business Development Officer | JANX Stock News - GuruFocus
Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer - Bluefield Daily Telegraph
Northern Trust Corp Buys 42,302 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
Cantor Fitzgerald Brokers Raise Earnings Estimates for JANX - Defense World
Q2 EPS Estimate for Janux Therapeutics Boosted by Analyst - Defense World
Janux Therapeutics Reports Increased Q1 Losses Amid R&D Expansion - TipRanks
Trend Tracker for (JANX) - news.stocktradersdaily.com
Leerink cuts Janux Therapeutics price target to $89, keeps Outperform By Investing.com - Investing.com India
Janux Therapeutics Inc (JANX) Gets a Hold from Scotiabank - The Globe and Mail
Promising Pipeline and Strategic Advancements Justify Buy Rating for Janux Therapeutics Inc - TipRanks
Janux Therapeutics price target lowered to $36 from $41 at Scotiabank - TipRanks
Janux Therapeutics (JANX) Reports Q1 EPS Loss, Maintains Strong Cash Position - GuruFocus
Scotiabank Adjusts Janux Therapeutics (JANX) Price Target Amid T - GuruFocus
Positive Buy Rating for Janux Therapeutics Inc. Driven by Promising Clinical Data and Strong Financial Position - TipRanks
Decoding Janux Therapeutics Inc (JANX): A Strategic SWOT Insight - GuruFocus
Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights - BioSpace
Janux Therapeutics Inc: Undervalued Growth Potential Amid Recent Stock Pullback - TipRanks
Janux Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Janux Therapeutics (JANX) Advances Clinical Trials for JANX007 | JANX Stock News - GuruFocus
Janux Therapeutics reports Q1 EPS (38c), consensus (39c) - TipRanks
BRIEF-Janux Therapeutics Q1 Basic EPS USD -0.38 - TradingView
Buy Rating for Janux Therapeutics Inc. Driven by Strategic Advancements in Prostate Cancer Treatment with JANX007 - TipRanks
Janux Therapeutics (NASDAQ:JANX) Shares Gap Down After Insider Selling - Defense World
Buy Rating for Janux Therapeutics Inc: Promising PFS Data and Attractive Valuation - TipRanks
Janux commences Phase Ib studies in trial for prostate cancer treatment - Clinical Trials Arena
Buy Rating for Janux Therapeutics Inc: Promising Clinical Trial Results and Positive Outlook for JANX007 - TipRanks
Janux Therapeutics Inc expected to post a loss of 39 cents a shareEarnings Preview - TradingView
Janux Therapeutics, Inc. (JANX): Among Unknown Billionaire Phill Gross’ Stock Picks with Huge Upside Potential - Insider Monkey
Janux Therapeutics begins phase 1b trial for prostate cancer therapy - Investing.com
Janux Therapeutics begins phase 1b trial for prostate cancer therapy By Investing.com - Investing.com India
Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates - Business Wire
Is Janux Therapeutics, Inc. (JANX) the Best Small Cap Stock to Buy with the Biggest Upside Potential? - Insider Monkey
0.56%
2.68%
자본화:
|
볼륨(24시간):